Raymond James Downgrades Exact Sciences (EXAS) to Outperform

Go back to Raymond James Downgrades Exact Sciences (EXAS) to Outperform

Exact Sciences (EXAS) PT Lowered to $125 at Stifel

November 3, 2021 6:44 AM EDT

Stifel analyst Daniel Arias lowered the price target on Exact Sciences (NASDAQ: EXAS) to $125.00 (from $145.00) while maintaining a Buy rating.

The analyst commented, "EXAS's 3Q saw the company miss on Screening (Cologuard) revenues, and lower the outlook for 4Q - as... More